Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mylan's Acquisition Strategy Now Focuses On "Bolt-Ons"

This article was originally published in The Pink Sheet Daily

Executive Summary

After three transformative acquisitions, the company aims for 15% CAGR between 2011 and 2013.

You may also be interested in...



Mylan Breathes Life Into Its Specialty Pharma Unit

In its first investor meeting in four years, Mylan lays out plans to barge over the generics industry’s post-2013 so-called ‘reverse patent cliff’ by focusing on high-barrier-to-entry products – including generic Advair – and portfolio and geographic diversification.

India, Japan Shake Hands For Faster Entry Of Generics But Market Realities May Be Tougher To Handle

MUMBAI/TOKYO - Introduction of non-discriminatory or national treatment clauses for Indian generic companies in the latest trade agreement between India and Japan will facilitate wider access for Indian generic firms to the world's second-largest pharma market, but analysts predict headwinds await before companies get a real bang for their buck

Bioniche Purchase Will Move Mylan Into Generic Injectables Market

Bioniche Pharma will be combined with UDL Laboratories to create new Mylan Institutional unit.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071877

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel